Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Illumina: Teva Pharmaceutical Exclusive Distributor of Verifi Test in Israel

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/01/2013 | 01:27pm CET
   By Melodie Warner 
 

Illumina Inc. (>> Illumina, Inc.) said Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)) will be the exclusive distributor of the verifi prenatal test in Israel under a five-year agreement.

Financial terms weren't disclosed.

Illumina paid $350 million in February to buy Verinata Health Inc., which gave it access to Verinata's verifi prenatal test, the broadest non-invasive prenatal test currently available for high-risk pregnancies.

The company said the MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality.

The MOR Institute will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata.

Illumina said the patient registry developed through this collaboration will be the largest and most extensive of its kind.

Illumina shares closed Friday at $74.84 and were inactive premarket. The stock is up 35% this year.

Write to Melodie Warner at melodie.warner@dowjones.com

Stocks mentioned in the article : Illumina, Inc., Teva Pharmaceutical Industries Ltd (ADR)
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
09:30a TEVA PHARM MAY FIRE 6,000 WORKERS : Israeli media report
03/20 TEVA PHARMACEUTICAL INDUSTRIES LTD ( : TEVA) Launches Minastrin Generic In The U..
03/16 TEVA PHARMACEUTICAL INDUSTRIES : New Findings Reported from Teva Pharmaceutical ..
03/16 TEVA PHARMACEUTICAL INDUSTRIES : Announces Launch of Authorized Generic of Minas..
03/13 TEVA PHARMACEUTICAL INDUSTRIES : to Present at the Barclays Global Annual Health..
03/13 OBEROI REALTY : Samsung leases 1.1 lakh square feet for office in mumbai for nin..
03/12 TEVA PHARMACEUTICAL INDUSTRIES : "Next 4 months most interesting in Teva's histo..
03/12 TEVA PHARMACEUTICAL INDUSTRIES : Philips Israel incubator selects 9 projects
03/09 TEVA PHARMACEUTICAL INDUSTRIES : Announces Launch of Generic Pristiq® in the Uni..
03/09 TEVA PHARMACEUTICAL INDUSTRIES : Announces Priority Review Granted by FDA for SD..
More news
Sector news : Pharmaceuticals - NEC
03/22 MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
03/20 FTSE rises to record close after Article 50 trigger date set
03/17DJPFIZER : Files 8K - Other Events
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05:26a Teva Pharm may fire 6,000 workers
03/21 UPCOMING EVENTS : Alder's Migraine Test, Paratek's Antibiotic
03/21 Biotechs under pressure after Trump (again) decries high drug prices
03/21 Selling Or Trimming Reasons Within My 86 Stock Portfolio
03/20 Swiss Generic Manufacturer Siegfried Increased Sales And EBITDA
Advertisement
Financials ($)
Sales 2017 23 456 M
EBIT 2017 7 071 M
Net income 2017 4 011 M
Debt 2017 25 854 M
Yield 2017 3,69%
P/E ratio 2017 8,28
P/E ratio 2018 8,02
EV / Sales 2017 2,52x
EV / Sales 2018 2,34x
Capitalization 33 153 M
More Financials
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 46,0 $
Spread / Average Target 41%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yitzhak Peterburg President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL IN..-13.45%33 153
JOHNSON & JOHNSON9.59%342 277
ROCHE HOLDING LTD.7.52%217 164
PFIZER INC.6.13%205 273
NOVARTIS AG0.47%194 072
MERCK & CO., INC.7.86%174 344
More Results